Protocol 2012-0252
November 11, 2016
Page 1
THE UNIVERSITY OF TEXAS MD 
ANDERSON CANCER CENTER
 
DIVISION OF CANCER MEDICINE
 
An Observational Study of cabozan tinib and Androgen Ablation in Pa tients with
Androgen-Dependent Metastatic Prostate Cancer
 
Lead Institution : The University of [LOCATION_007] MD Anderson Cancer Center
 
Principal Investigator:  [INVESTIGATOR_798737], M.D., Ph. D.
[ADDRESS_1101745], Unit 1374Houston, TX 77030Telephone: (713) 792-2830Fax: ([PHONE_5731]
E-mail: [EMAIL_1908]
 
 
 
 
 
       
 
        
Protocol 2012-0252
November 11, 2016
Page 2
1.0 Objectives
 
Primary Objective(s) / Endpoint(s)
In this study, we will explore the safety and clinical efficacy of caboz antinib combined 
with androgen ablation in men with newl y diagnosed androgen-dependent pr ostate cancer 
based on progression free survival. The primary end points are:
1.To assess the tolerance and safety of cabozantinib in combination with a ndrogen 
ablation in this patient group.
2.To estimate the time to castrate-resistant progression defined by [CONTACT_31617] o f the following: 
(a) radiographic progression (using RECIST 1.1 for visceral disease a nd PCWG2 for 
Bone Scans), (b) receipt of additional anti-cancer therapy, or (c) cl inical progression 
warranting discontinuation from the study as judged by [CONTACT_74079].
3.To collect and bank blood and tissue specimens for future hypothesis-gen erating 
studies.
 
Secondary Objective(s) / Endpoint(s)Secondary endpoints will include:
1.   Overall Survival
2.   Radiologic responses3.   Biomarker modulation (for example PSA, CTC, serum cytokine profi les, bone specific 
alkaline phosphatase, uri ne n-telopeptides)
4.   Tumor pharmacodynamic measures (molecular-pathologic analysis o f c-Met/VEGFR
signaling pathways using metastatic tissue samples).
 
 
2.0 Background
Cabozantinib (XL184) is a novel small molecule inhibitor of multiple re ceptor tyrosine
kinases (RTKs) that promote tumor cell proliferation and/or angiogenes is including RET, 
MET, VEGFR2/KDR, and KIT. In a recently reported phase II randomized d iscontinuation 
study of cabozantinib in patients with advanced solid tumors, a high prop ortion of patients 
with mCRPC achieved clinically sign ificant responses while on therapy characterized by 
[CONTACT_798752], reduc tions in lymphadenopathy, reductions in pain, a nd improvement in 
bone scans(1). These results are attributed to the fact that overexpress ion of MET (and/or its
ligand HGF) correlates with prosta te cancer progression and the develo pment of metastasis
(2-4). Based on these encouraging results, a multi-center, non-random ized expansion (NRE)
cohort for patients with m CRPC has been initiated. We now propose to study the potential
safety and benefit of cabozantinib in patients with metastatic andro gen-dependent
prostate cancer.
 
The front-line paradigm for the treatment of metastatic androgen-depe ndent prostate cancer 
remains disruption of androgen receptor signaling (5). Despi[INVESTIGATOR_798738], 
however, all patients eventually dev elop castrate-resistant progressi on, a disease state 
responsible for 32,[ADDRESS_1101746] ye ar in the [LOCATION_002] (6, 7). Re cent advances in
tumor biology have elucidated growth-promoting pathways that contribut e to the 
development of castrate-resistant disease. Importantly, these oncoge nic pathways provide 
crosstalk between the â€œepi[INVESTIGATOR_752402]â€ and the â€œstromal compart mentâ€ (8). For
Protocol 2012-0252
November 11, 2016
Page 3
 
example, stromal elements within bone â€“ the most frequent organ site for p rostate cancer 
metastases - promote the evolution of castrate-resistant disease. The r ationale to disrupt this 
crosstalk has led to the discovery of drugs that target tumor stromal el ements in additional to
the cancer epi[INVESTIGATOR_1231] (9).
 
There is increasing evidence from data derived from primary human tumors a ndpre- clinical
models that Met is a critical oncogenic pathway that contributes to the evo lution of castrate-
resistant disease. For example, Met is upregulated by [CONTACT_798753]-
proliferative effect of Met inhibitors is greater in castrate-resistant versus androgen-
dependent cell lines (10, 11). Further more, the anti-tumor effect of Me t inhibitors is greatly 
enhanced when combined with androgen ablation therapy in pre-clinical mo dels (11). These
results suggest the hypothesis that c ombining Met inhibition with andro gen ablation will
prevent (or delay) the development of castrate-resistant disease.
 
In the present study, we will explore this hypothesis by [CONTACT_798754], androgen-depend ent metastatic 
disease. Data from our own institution suggest that the median time to pr ogression (as 
defined by [CONTACT_798755]-resistant disease) in unselect ed patients treated with 
androgen ablation alone is approxima tely 24 months. However, in a subset  of patients with 
â€œhigh-volumeâ€ disease (>3 bone lesions and/or visceral metastases), the median time to 
progression is 11.2 months (12).
 
 
3.0 Eligibility Criteria
 
Inclusion Criteria:
 
1.   Histologic proof of prostate adenocarcinoma
 
2.   Newly diagnosed Androgen-Dependent Prostate Cancer. Patients al ready on ADT are 
eligible as long as the time from initiation of LHRH analog or antagonis t is not greater
than 3 months.
 
3.  Metastatic disease on bone scan and/or involvement of soft tissue s (lymph nodes and/or 
viscera) by [CONTACT_3610], PET/CT, or MRI
 
4.   PSA > 1 ng/ml, unless anaplastic  features are present (acco rding to eligibility 10)
 
5.   Life expectancy from a co-morbid illness > 3 years
 
6.   ECOG performance status Â”
7.   Patients must have adequate or gan function as defined by:
[CONTACT_798756]&Â•XO (unless due to bone marrow infiltr ation by [CONTACT_798757] 
>500/ml are allowed)
x+JEÂ•J m/dL (unless due to bone marrow in filtration by [CONTACT_798758]>8 
gm/dL)
xTotal bilirubin Â”WL mes the upper limit of normal. Fo r patients with known Gilbertâ€™s
Protocol 2012-0252
November 11, 2016
Page 4
disease, total bilirubin should be Â”mg/dL
xplatelet count Â•P m3 (unless due to bone marrow in filtration by [CONTACT_798759] >50,000/ml are allowed)
xAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) Â”uULN if
no liver involvement, RUÂ”uULN with liver involvement
 
xLipase < 2 x the upper limit of normal
 
xUrine protein/creatinine ratio 83&5Â”
 
xSerum phosphorus Â•LLN
 
xestimated creatinine clearance of Â•40 ml/min.
8.   Prior ADT is allowed if it was an adjunct to definite local therapy , was given for < [ADDRESS_1101747] to definitive local therapy, was given for < [ADDRESS_1101748] 12 months before initiating therapy for metastat ic disease.
10. Patients with â€œanaplasticâ€ featur es are eligible for this trial as defined by [CONTACT_9655]:
 
a) Any of the following metastatic presentations: exclusive visceral metastases, 
radiographically predominant lytic bone metastases identified by [CONTACT_260858] X-ray or CT 
scan, bulky (>[ADDRESS_1101749] dimension) lymphadenopathy or high-grade ( gleason
>8) tumor mass in the prostate/pelvis.
 
b) Low PSA ( Â”10 ng/ml) at initial presentation (prior to androgen ablation or at 
symptomatic progression in the castrate-setting) plus high volume ( Â•ERQH
metastases.
 
c) Elevated serum LDH ( Â•[8/1RUHOHYDWHG serum CEA ( Â•[8/1LQ the 
absence of other etiologies.
 
d) Short interval Â”GD\VWR castrate-resistant progression following initiation of 
hormonal therapy.
11. Sexually active fertile subjects, and their partners, must agree to u se medically accepted 
methods of contraception (eg, barrier methods, including male condom, f emale condom,
or diaphragm with spermicidal gel) during the course of the study and for [ADDRESS_1101750] dose of study drug(s).
 
 
Exclusion Criteria:
 
1.   Biological agents (antibodies, immune modulators, cytokines, or vaccines) or 
radionuclide treatment within [ADDRESS_1101751] has uncontrolled or significant intercurrent illness including, but not limited 
to, the following conditions:
 
xChronically uncontrolled hypert ension, defined conventionally a s consistent and 
repeated systolic pressures a bove 140 mmHg or dia stolic pressur es above 90 mmHg 
despi[INVESTIGATOR_6698]-hypertensi ve therapy. This may  be better establish ed with home BP 
readings than with clinic visit results. There is no criterion related to a specific BP 
result required for eligibility , nor are acute BP elevations th at are related to iatrogenic 
causes, acute pain, or other transi ent reversible causes consid ered to be an exclusion 
criteria. The intent is to exc lude patients with chronically un controlled hypertension 
that might be further exa cerbated by [CONTACT_408279].  
xOther cardiovascular disorders such as symptomatic congestive hear t failure (CHF), 
unstable angina pectoris, clinically-significant cardiac arrhythmias , history of stroke
(including TIA, or other ischemic e vent) within 6 months of study trea tment,
myocardial infarction within 6 months of study treatment, history of th romboembolic
event requiring therapeutic anticoagulation within 6 months of study tr eatment or 
main portal vein or vena cava thrombosis or occlusion.
 
xGastrointestinal disorders particularly those associated with a high r isk of 
perforation or fistula formation including:
 
oAny of the following at the time of screening
 
a) intra-abdominal tumor/metast ases invading GI mucosa b) 
active peptic ulcer disease,
c) inflammatory bowel disease (including ulcerative colitis and Crohnâ€™ s 
disease ), diverticulitis, cholecystitis, symptomatic cholangitis or 
appendicitis
 
oAny of the following within [ADDRESS_1101752] dose of study 
treatment:
 
a)  history of abdominal fistula 
b) gastrointestinal perforation
c) bowel obstruction or gastric outlet obstruction
 
d) intra-abdominal abscess. Note: Complete resolution of an intra-ab dominal 
abscess must be confirmed prior to initiating treatment with cabozantin ib
even if the abscess occurred more that 6 months ago.
 
oGI surgery (particularly when associated with delayed or incomplete  
healing) within 28 days.  Note: Complete healing following abdominal 
Protocol 2012-[ADDRESS_1101753] has a previously-identified allergy or hypersensiti vity to components of 
the study treatment formulation.
 
8. Oral corticosteroids > 7.5mg predni sone (or prednisone equivalents) .
 
9. Prior treatment with cabozantinib.
 
10. The subject has a corrected QT int erval calculated by [CONTACT_798760] (QTcF)
>500 ms within 28 days before randomization.
 
 
4.0 Drug Information
 
4.1 Cabozantinib
 
Cabozantinib (XL184) is a new chemical entity that inhibits multiple RT Ks with 
growth-promoting and angiogenic properties. The primary targets of cab ozantinib
are RET, MET, VEGFR2/KDR, and KIT (Table 1).
 
Table 1: Cabozantinib(XL184) IC50 V alues in Biochemical, Enzymatic Assays
Kinase IC50 (biochemical) [nM]
RET 3.8
MET 1.8
VEGFR2/KDR 0.035
KIT I 4.6
ICSO, concentration required for 50 %target inhibition.
Treatment with cabozantinib shows rapid effects on the tumor endotheli um,
resulting in breakdown of the vasculature beginning 24 hours after ad ministration
of cabozantinib, thus suggesting potent anti-angiogenic effects of ca bozantinib.
These effects translate into significant tumor growth inhibition afte r cabozantinib
treatment in multiple tumor models including human medullary thyroid ca ncer
(MTC), human breast cancer, human lung carcinoma, and rat glioblastoma. Overall,
the data generated in vivo demonstrate that the target profile of cabozan tinib
translates to potent anti-angiogenic activity and potent anti-tumor ef ficacy.
Protocol 2012-[ADDRESS_1101754] been enrolled in a placeb o-
controlled blinded Phase 3 study. Clinical data are available from nine studies of 
cabozantinib including four Phase 1 studies, one Phase 1b/2 study, th ree Phase 2 
studies, and one Phase 3 study. A summary of the availability of clini cal data for 
cabozantinib, including the data sour ces and the dates of data cutoffs ,i ss h o w n  
in the table below.
Study Data SetNumber of 
SubjectsCutoff D ate
XL184-00I SAEs 85 04 May 20 11
Clinical database (AEs) 86a01 March 2011
Clinical database(antitumoractivity) 85 16 Apr il2010
XL184-002 SAEs 26 04 May 2011
Clinical database (AEs) 19 01 March 2011
Clinical database(antitumoractivity) --
XL184-008 SAEs 23 04 May 20 11
Clinical database (AEs) 11 01 March 2011
Clinical database(antitumoractivity) --
CA205 -00I SAEs 3 04M ay2011
IXL184 -014
Clinical database (AEs) 3 01 March 2011
Clinical database(antitumoractivity) --
XL184-201 SAEs 222 04 May 20 11
Clinical database (AEs) 214 01 March 2011
Clinical database(antitumoractivity) 105 28 Apri12010b
XL184-202 SAEs 93c04 May 20 11
Clinical database (AEs) 77 01 March 2011
Clinical database(antitumoractivity) 54 01 March 2011
XL184-203 SAEs 531 04 May 20 11
Clinical database (AEs) 174d01 March 2011d
Clinical database (AEs) 490d09M ay2011d
Clinical database(antitumoractivity) 490 09May20 11
XL184-205 SAEs 19 04 May 20 11
Clinical database (AEs) 17 01 March 2011
Clinical database(antitumoractivity)
XL184-301 SAEs 330 04 May 20 11
AE, adverse event; SAE, serious adverse event.
a. One subject withdrew from and re-enrolled in XL184-001. This subject is counted once in 
enrollment, demographic tables, and SAE analyses (N = 85) and t wice in adverse event analyses 
(N= 86).
b. Data available for Groups A and B.
c. Includes subjects treated with the combination of cabozantini b plus erlotinib as well as those
treated with cabozantinib alone. One subject discontinued during  the erlotinib Rum-In Stage 
and never received any dose of cabozautinib.
d. The summary of pooled adverse events presented in Section 5.4. 1 includes data from 174 subjects 
Protocol 2012-0252
November 11, 2016
Page 8
from Study XL184-203 as of the cutoff date of 01 March 2011 for the  open-label l2-week Lead-In 
Stage; for Study XL184-203 only, an updated safety analysis based  on data from 490 subjects 
(Lead-In Stage) as of the cutoff date of 09 May 2011 was also co nducted for the RDT Cohorts of 
the study (see Section 5.1.7 for description of cohorts), and the  safety profile was not significantly 
changed from the [ADDRESS_1101755] bee n
studied in open-label clinical trials with cabozantinib, including tre atment with
cabozantinib as a single agent, as well as cabozantinib in combinatio n with
temozolomide and radiation therapy , and cabozantinib in combination wi th
erlotinib.
 
4.1.3 Adverse Events
The general adverse event profile of  cabozantinib includes GI symptoms (such as 
nausea, vomiting, and diarrhea), fatigue, anorexia, palmar-plantar erythrodysesthesia (PPE) syndrome, skin rash, elevated ALT and AST, i ncreased
pancreatic enzymes with rare cases of  pancreatitis, as well as side e ffects
associated with inhibition of VEGF signaling such as thrombotic event s( e g ,
pulmonary embolism [PE] and deep vein thrombosis [DVT]), hypertension,proteinuria, hemorrhagic events, and rare cases of gastrointestinal [G I]
perforation and rectal/perirectal abscess. Arterial thromboembolism (transient
ischemic attack [TIA], myocardial infarction [MI]) have been reported rarely.
 
4.1.4 Serious Adverse Events
Out of all 561 subjects enrolled in open-label clinical trials with cab ozantinib 
(XL184), 224 subjects (40%) experienced one or more SAEs, and 96 sub jects 
experienced one or more SAE that was assessed to be related to treatment with
cabozantinib. This total includes two late-breaking cases (one case of abdominal
distension and failure to thrive in Study XL184-201 and one fatal respir atory
failure in Study XL184-203) that were reported after the data cut- off. A cross 
all open-label studies, the most comm only reported events, regardless o f 
relationship to cabozantinib, we re PE (in 21 subjects), convulsion (in 1 7
subjects), DVT (in 13 subjects), pneumonia (in 13 subjects), vomitin g( i n1 2  
subjects), abdominal pain (in 11 subjects), diarrhea (in 11 subjects), nausea (in
11 subjects), dehydration (in 10 subjects), and dyspnea (in eight subje cts). The
most commonly reported events across all open-label studies that were a ssessed
as drug-related were PE (in 14 subjects), diarrhea (in nine subjects), DVT (in
seven subjects), nausea (in seven subj ects), hypertension (in five subj ects),
thrombocytopenia (in five subjects), dehydration (in four subjects), vomiting (in
four subjects), abdominal pain (in thr ee subjects), and perirectal abs cess (in
Protocol 2012-0252
November 11, 2016
Page 9
three subjects). In addition, one late- breaking case of reversible post erior
leukoencephalopathy syndrome (RPLS ) was reported after the data cut-o ff in
the double-blinded placebo-controlled Study XL184-301.
 
4.1.[ADDRESS_1101756] dose of study drug;
the majority was due to disease progression, and 5 deaths were assessed  to be
related to cabozantinib: GI hemorrhage (in one subject), PE (in two subj ects),
respi[INVESTIGATOR_1399] (in one subject ), and hemoptysis (in one subject).
 
4.1.6 Clinical Pharmacokinetics
In Exelixis study XL184-001, in which doses are expressed in terms of t heir L-
malate salt weight (see Appendix J f or freebase weight equivalents), a
preliminary PK analysis has been performed for 74 subjects. The cut-o ff date for 
the data used for this PK analys is is 02 September 2008. Pharmacokine tic 
results from Cohorts 1-9 (0.08-11.52 mg/kg, Intermittent 5&9, PIB) sho w that 
systemic exposure (Cmax and area under the plasma drug concentration tim e
curve from time [ADDRESS_1101757] quantifiable concentration following dosin g 
[AUC0-last]) values increased gene rally dose-proportionally with inc reasing 
cabozantinib dose. Terminal phase ha lf-life (t1/2, z) values were long ( range:
59.1 to 136 hours). Data from Cohorts 10-13 (175 mg qd PIB; 265 mg qd P IB;
175 mg qd capsule; 250 mg qd capsule) and Cohort 99 (175 mg qd capsule)  
show that drug accumulation (base d on Cmax and AUC0-24 values) at stea dy-
state after daily dosing is approximately 4- to 6-fold.
 
In addition, exposure values from PIB (Cohorts 10) or Capsule (Cohort s 12 
and 99) are compared in Table 2. The data show that cabozantinib exposure  
(AUC) values from capsule cohorts are about 2.0 fold greater than those 
observed in the respective PIB cohort.
 
Table 2: Comparison of Exposure from PIB (Cohorts 10) or Capsule
(Cohorts 12& 99)
Day 19 Cmax
(ng/mL)Day 19 AUC 
(ngÃ—h/mL)
Cohort 10
175 mga qd PIB, n = [ZIP_CODE] [ZIP_CODE]
Cohort 12 and 99
175 mga qd capsule, n = 192310 [ZIP_CODE]
AUC, area under the plasma drug concentration time 
curve; Cmax, maximum plasma concentration; PIB, powder in bottle; qd, once daily.
 
Data from 18 subjects in XL184-201 (GB M) are available as of 26 Janua ry 2009.
The data show that pre-dose concentration values at C1D15 are consiste nt with
those reported in the Phase 1 s etting: 1800 Â± 868 ng/mL (n =18) versus  1920 Â±
751 ng/mL (n = 16). In addition, the p eak to trough concentration ratio s at steady-
Protocol 2012-0252
November 11, 2016
Page 10
state are moderate, with a value approximately equal to unity.
 
Pharmacokinetic analysis of cabozantinib has not been studied in subje cts 
receiving a capsule dose of 125 mg (salt weight) qd, but simulated expo sure 
values are expected to be about 70% of those from 175 mg (salt weight). Based on the simulated data, exposure values from the 125-mg (salt weight ) 
cohort or the 175-mg (salt weight) cohort are statistically different: 9 5% 
confidence interval for AUC values are [ZIP_CODE] Â± 1022 vs. [ZIP_CODE] Â± 1730ngÃ—h/mL, respectively. In addition, the simulated steady-state averag e 
concentration from cabozantinib at 125 mg (salt weight) is 1100 ng/mL.
4.1.7 Comparative Bioavailability Stu dy of Cabozantinib Tablet and Cap sule
Formulations in Healthy Adult Subjects (Study XL184-005)
 
Study XL184-[ADDRESS_1101758] (100 mg cabozantinib, do sed as one
100-mg tablet) or Reference (100 m g cabozantinib, dosed as two 50-m g
capsules), according to a randomization scheme. Each dosing was admini stered
under fasting conditions, and blood samples were collected up to [ADDRESS_1101759] after each treatment to assess plasma cabozanti nib PK.
Based on the preliminary PK data from 23 subjects who completed both treatments, after a single oral dose of cabozantinib at 100 mg, the termin al- phase
half-life (t
1/2, z) of cabozantinib appeared to be s imilar for both tablet and capsule
formulations, with approximately mean values of 110 hours. The media nt i m et o
the maximum plasma concentration (tmax)was [ADDRESS_1101760] variabi lity for the
maximum plasma concentration (C max) and the area under the plasma drug 
concentration time curve (AUC) va lues were observed for both formulatio ns
(coefficient of variation [CV]% C max: 51% for the tablet f ormulation, 61% for 
the capsule formulation; CV% for the AUC from time zero to the last
quantifiable timepoi nt or to infinity [AUC 0-lastor AUC 0-inf]: 40-43% for the tablet
formulation, 43% for the capsule fo rmulation.) The geometric mean C maxof the
tablet formulation was approximate ly 39% higher than the value observ ed for the
capsule formulation. The geometric mean AUC 0-lastand AUC 0-infvalues for the
tablet formulation were also higher (15% and 19%, respectively) than th ose
observed for the capsule formulation. However, due to the high within-formulation variability observed, no
statistical difference in exposure between the
two formulations was apparent.
4.1.[ADDRESS_1101761] of Food on the Bioavailab ility of Cabozantinib in Health y Adult Subjects
(Study XL184-004)
 
Study XL184-[ADDRESS_1101762] ([ADDRESS_1101763]) or 
Reference (175 mg cabozantinib, dosed as one 100-mg capsule and three 25 -
mg capsules under fasting conditions). Blood samples were collected up t o [ADDRESS_1101764] afte r each treatment to assess plasm a
cabozantinib pharmacokinetics.
 
Based on the preliminary PK data from 46 subjects who completed both treatments, a high-fat meal did not appear to alter the terminal t
1/2, zof 
cabozantinib [mean t 1/2, z: 131 hours (fed) vs 128 hours (fasted)]. The high-fat 
meal significantly increased the median t maxto 6 hours from 4 hours (fasted). The
high-fat meal also significantly increased both the cabozantinib C maxand AUC 
values by 39% and 56%, respectivel y. The geometric mean ratio of C max 
fed/fasted was 1.39 (90% CI: 1.16-1.67) , and the geometric mean ratio of AUC 0-
lastfed/fasted was 1.56 (90% CI: 1.34-1.80). Based on this result, cabo zantinib
should be taken on an empty stomach (fasting is required 2 hours before a nd 1
hour after each cabozantinib dose).
 
4.1.9 Composition, Formulation, and Storage
At study sites, all study medication will be stored at room temperature. F or 
additional information relating to the study drug formulation and compo sition, 
please see the current version of the investigatorâ€™s brochure.
 
Destruction of CabozantinibIf cabozantinib is to be destroyed on site, it is the Investigatorâ€™s resp onsibility to
ensure that arrangements have been ma de for disposal and that procedures  for 
proper disposal have been establishe d according to applicable regulatio ns, 
guidelines, and institutional procedures. Appropriate records of the d isposal 
must be maintained.
 
 
4.1.10 Investigational Treatment
Chemical Name: [CONTACT_7916]: N-{4-[(6,7-dimethoxyquinolin-4-
yl)oxy]phenyl}- Nâ€™-(4-fluorophenyl)cyclopropa ne-1,1-dicarboxamide, (2S)-
hydroxybutanedioate
 
4.1.11  Cabozantinib Tablets
Cabozantinib tablets are supplied as film coated tablets containing cabozantinib
malate equivalent to 20 mg and 60 m g of cabozantinib and contain
microcrystalline cellulose, lactose anhydrous, hydoxypropyl cellulo se, 
croscarmellose sodium, colloidal silicon dioxide, magnesium stearate a nd 
OpadryÂ® yellow. All tablet strengths are prepared from a common blend and are
distinguished by [CONTACT_7823]. The 20 mg tablets are round and the 60 mg tablets  are
oval. The components of the tablets are listed in Table .
 
 
Protocol 2012-0252
November 11, 2016
Page 12
Table 4-1: Cabozantinib Tablet Components and Composition
 
Ingredient Function % w/w
 
Cabozantinib malate (25% drug load as cabozantinib) Active Ingredien t3 1 . 7
Microcrystalline Cellulose (Avicel PH-102) Filler 38.9
Lactose Anhydrous (60M) Filler 19.4
Hydroxypropyl Cellulose (EXF) Binder 3.0
Croscarmellose Sodium (Ac-Di-Sol) Disenegrant 6.0
Colloidal Silicon Dioxide, Glidant 0.3
Magnesium Stearate Lubricant 0.75
Opadry Yellow Film Coating which includes:  
-HPMC 2910 / Hypromellose [ADDRESS_1101765] used.
 
4.2 Androgen Deprivation Therapy
A luteinizing hormone-releasing hormone (LHRH) analog or antagonist , such as 
Leuprolide (Lupron),Goserelin (Zoladex) or Degarelix (Firmagon) will b e used as 
androgen deprivation therapy (ADT) .  Anti-androgens (such as bicalu tamide) may be 
used for up to 4 weeks to prevent a â€œflare-responseâ€.   
 
 
5.0 Treatment Plan
 
All patients will receive androgen ablation therapy, either by [CONTACT_798761]â€“releasing hormone super-agonist (of any formulation), LHRH a ntagonist, or 
surgical castration. The use of anti-androgens to prevent a â€œflare-resp onseâ€ is permitted
for up to [ADDRESS_1101766] received up to 3 months of an drogen
deprivation therapy prior to initia ting cabozantinib. The time-to-pro gression data will be
calculated from the start of hormonal therapy, not fro m the date of initiation of study d rug 
Protocol 2012-0252
November 11, 2016
Page 13
cabozantinib.
 
All patients will receive cabozantin ib at a starting dose of 60mg PO q d ay. Study cycles 
will be 3 weeks in duration (+/- 3 day s). All patients will stay on treatm ent as long as
they are benefitting.
 
Patients will be removed from study if they meet any of the following crite ria:
xDisease progression
xUnacceptable toxicity
xPatient decision to withdraw
xPalliative radiation involving more than one site
xIn the judgment of the investigator , further treatment would not be in th e best interest
of the patient.
xReceipt of any additional prostate  cancer specific therapy as p rescribed by [CONTACT_30780].
 
 
6.0 Patient Evaluations
Pre-Study Treatment (to be completed within 6 weeks of study entry) :
xMedical history will be recorded, along with performance status, AE asse ssment,
concomitant medications, vital signs  (temperature, blood pressure, b reathing rate,
and heart rate), weight and di sease related symptoms.
 
xPhysical exam, CBC with differential and platelets, serum chemistries (s odium,
potassium, chloride, carbon dioxide , magnesium, glucose, calcium, phos phorus, 
BUN, albumin, total protein, bone specific and total alkaline phosphata se, creatinine,
ALT and/or AST, total bilirubin, direct bilirubin, LDH, Lipase, TSH,  free T4),
testosterone, PSA, PT/ PTT, urinalysis and urine for UPCR (24 hr uri ne for total
protein if UPCR is >1) and N- telopeptides, radiographic studies (Bone Sc an, CT
scan of the Chest/Abdomen/Pelvis â€“ PET/CT or MRI scans are also ac ceptable), 
Electrocardiogram (ECG) and specimens for correlative studies (see Se ction 6.1).
 
On-Study Treatment (evaluations have a standing window of allowance of +/- 3 days ):
xWeeks 1 through 12 : Patients will be evaluated every 3 weeks after the start of Week
1 until the end of Week 12 (ie, end of Week 3, end of Week 6, end of Week 9, and end
of Week 12).  Evaluations will include physical exam, vital signs, weig ht, toxicity
review, concomitant medications, C BC with differential and platelets, serum
chemistries (sodium, potassium, chloride, carbon dioxide, magnesium, glucose,
calcium, phosphorus, BUN, albumin, total protein, total alkaline pho sphatase,
creatinine, ALT and/or AST, total bilirubin, direct bilirubin, LDH), and optional
specimens for correlative studies (see Section 6.1). Imaging studies wi ll be repeated at
Week 12. If there was no evidence for soft tissue disease in the thorax at baseline, 
repeat CT scans of the chest m ay be omitted at the discretion o f the treating physician.  
Adverse events will be recorded at each visit.
oPatients on therapeutic  Coumadin will have PT/PTT testing every  week for the first 
3 weeks.
oTSH, free T4, and Lipase will  be measured every 3 weeks up to a nd including Week 
Protocol 2012-0252
November 11, 2016
Page 14
12.  If no abnormalities are detecte d by [CONTACT_10585] 12, measurements m ay be repeated
every 12 weeks. If abnormalities are  detected, the frequency of testing will be at the 
discretion of the tre ating physician.
oPSA, bone specific alkaline phosphatase (BSAP), urinalysis and urine f or n-
telopeptides will be measured ever y 6 weeks. UPCR will be performed only if 
urinalysis reveals >100 mg/dL.
 
xAfter Week 12 until completion of study treatment : Patients treated beyond week 12
will be evaluated every 6 weeks. Eva luations will include physical exam , vital signs, 
weight, toxicity review, concomita nt medications, CBC with differentia l and platelets,
serum chemistries (sodium, potassium, chloride, carbon dioxide, magnes ium, glucose, 
calcium, phosphorus, BUN, albumin, total protein, total alkaline phosphatase, creatinine,
ALT and/or AST, total bilirubin, direct bilirubin, LDH), and optional specimens for 
correlative studies (Section 6.1) . Imaging studies should be repeated every 12 weeks or 
sooner at the discretion of the treating physician if disease progress ion is suspected.
 
oPSA, bone specific alkaline phosphatase (BSAP), urinalysis and urine f or n-
telopeptides will be measured ever y 6 weeks. UPCR will be performed only if 
urinalysis reveals >100 mg/dL.
oTSH, free T4, and Lipase will  be measured every [ADDRESS_1101767] 6 months and fo r whom travel to MDACC 
is prohibitive (e.g. patients th at live out of state) may elect  to forgo q6 week clinic 
visits and have labs drawn local ly. However, these patients must  return every 12 weeks 
when scans are performed. 
oAll concomitant medications  (including over-the-counter and nut ritional supplements) 
must be recorded in the electroni c medical record or source, but  not the electronic 
database, GURU.
 
Post-Study treatment
xPatients will be followed for overall survival. Survival updates will ta ke place at [ADDRESS_1101768] review.
 
6.1 Correlative Studies (mandatory a t baseline, optional for subse quent time points)
x For all patients who provide informed consent, venous blood will be col lected for 
correlative studies to include multiplex analysis of cytokines, circula ting tumor 
cells (CTCs) will collected and distributed to [CONTACT_798780]â€™ s lab for 
processing and analysis. .. Sam ples will be collected at the followi ng time points:
baseline, Week 3, Week 6, Week 9, Week 12, every 6 weeks thereafter (f or patients
Protocol 2012-0252
November 11, 2016
Page 15
treated beyond Week 12), and at the time the patient completes treatment with
cabozantinib (either for disease progression, unacceptable toxicity , or patient
withdrawal, or receipt of additiona l prostate cancer specific t herapy as prescribed 
by [CONTACT_1963]). Additional historic tissue collection  will be obtained 
from the MD Anderson tissue bank w ith prior consent to LAB03-32 0 and PA13-
0247.
 
x For patients with metastatic disease to the pelvis that is accessible via trans-iliac biopsy,
unilateral or bilateral bone marrow biopsies/aspi[INVESTIGATOR_798739] (mandatory), at
Week 6 on treatment (optional), and a t the time the patient complete s treatment (optional) with
cabozantinib (either for disease progression, unacceptable toxicity , or patient withdrawal, or 
receipt of additional prostate can cer specific therapy as presc ribed by [CONTACT_1963]).
Alternatively, when tumor is not  accessible via the trans-iliac  approach (e.g. ischium ), image guided biopsy 
techniques (e.g. CT-guided) of me tastatic sites and biopsies of the primary tumor ( if in place) may be 
utilized. Aspi[INVESTIGATOR_798740] , circulating tumor cells (CTCs).  
Cores will be analyzed for modulation of signaling via the androgen rece ptor, the c-Met receptor,
and VEGFRs.  
x All left over samples will be stored and ba nked for future use,  including genetic 
testing, in the GU Biorepository (blood and bone marrow) and th e Prostate Tissue 
Bank (tissue).  
 
Protocol 2012-0252
November 11, 2016
Page 16
6.2 Study Calendar
 
On-study tests/visits that must occur within a defined time frame will ha ve a
standing window of allowanc e that is equal to +/- [ADDRESS_1101769] 3 
weeksEvery 3 Weeks
(for first 12
weeks) and
Every 6 weeks 
afterjEvery 
6
weeksWeek 6
onlyEvery 12 
Weeks 
End of
TreatmentFollow- Up
Medical History xa x      
Physical examination xax      
Height and Weight xax      
ECOG performance status xa       
Vital Signsfxax      
Baseline
Symptoms/Adverse EventMonitoring xa x     
Concomitant Medications xax      
CBC with differential andplatelets xax     
Serum Chemistrybxax      
Testosterone xa       
PT/PTT xaxi      
PSA, Bone Specific
Alkaline Phosphatasexa x    
Lipase xaXC  xc   
TSH, and free T4 xaXC  xc   
Urinalysis, UPCR, uNTx xa xg    
Imaging Chest, Abd Pelvisxa     xd   
Bone scan xa    xd   
ECG xa       
Survival Follow-up        xe
Blood for Correlative
Studiesh xx   x 
Unilateral or Bilateral BMA/BX for Correlative
Studies
h x  
x x 
a. Within [ADDRESS_1101770] of sodium, potassium, chloride, carbon d ioxide, magnesium,
glucose, calcium, phosphorus, BUN, albumin, total protein, total alka line phosphatase,
creatinine, ALT and/or AST, total & direct bilirubin, LDH
c. Repeat every [ADDRESS_1101771] revie w, or e-mail correspondence every 6 
months for survival.
f.  To include temperature, blood pressure, breathing rate, and heart rate
g. UPCR will be performed only if urinalysis reveals >100 mg/dL.
h. Mandatory at baseline, optional at subsequent time points.
i. For patients on therapeutic Coumadin. This lab may be checke d locally and Coumadin dosing regulated per 
treating physician
j.   Patients who are clinically stable for at least 6 months and for whom travel to MDACC is prohibitive (e.g. 
patients that live out of state) may elect to forgo q6 week clin ic visit and have labs drawn locally 
 
 
7.0     Dose Modifications/Toxicity Management
 
Patients will be treated until development of castration-resistant dis ease progression,
unacceptable toxicity, or patient withdrawal of consent.
 
Subjects will be monitored closely for AEs and instructed to notify thei r physician and/or 
study nurse immediately for any and all toxicities. Subjects experienc ing one or more AEs 
due to the study treatment may require a dosing delay, or reduction(s), in their dose in
order to continue with study treatment. Assessment of causality (chron ology, confounding
factors such as disease, concomitant medications, diagnostic tests, and previous
experience with the study treatment) should be conducted by [CONTACT_978] [INVESTIGATOR_1660] a s ub-investigator,
before a decision is made to modify the dose or to hold dosing temporaril y.
 
Permissible dose reductions are outlined in Table 3. Patients who cann ot tolerate [ADDRESS_1101772] 
effective dose will require brie f interruptions (e.g. 1 to 3 da ys per week) in the daily 
dosing of cabozantinib rather than a dose reduction. These inte rruptions are permissible at 
the discretion of the treating  physician and will be recorded f or data monitoring, reporting, 
and publication.
 
 
7.1 Warnings, Precautions, and Ma nagement of Anticipated Events
The general adverse event profile of  cabozantinib includes GI symptoms (such as nausea,
vomiting, and diarrhea), fatigue, anorexia, palmar-plantar erythrodys esthesia (PPE) 
syndrome, skin rash, elevated ALT and AST, increased pancreatic enzyme s with rare
cases of  pancreatitis, as well as side effects associated with inhibi tion of VEGF signaling
such as thrombotic events (eg, pulmonary embolism [PE] and deep vein t hrombosis
[DVT]), hypertension, proteinuria, hemorrhagic events, and rare cases of gastrointestinal
Protocol 2012-0252
November 11, 2016
Page 18
[GI] perforation and rectal/perirectal abscess. Arterial thromboem bolism (transient
ischemic attack [TIA], myocardial infarction [MI]) have been reporte dr a r e l y .
 
 
7.1.1 Management of Adverse Events
 
 
In the absence of an unacceptable cabozantinib-related toxicity and/o r clinical signs of 
disease progression, subjects may con tinue treatment at the discretion of the 
investigator. Subjects must be instructed to notify their physician imme diately for any
and all toxicities.
 
Guidelines for the management of AEs (i.e. dose interruptions and dos e reductions) are
presented in the next sections. Each dose reduction of cabozantinib sho uld be to one
dose level lower that the current dose. If study treatment of cabozanti nib is restarted
after being withheld or interrupted, t he subject should be instructed not to make up the
missed doses of cabozantinib.
 
The reason for treatment delay and reduced dose must be recorded in the me dical 
record.  Any dose interruption and/or treatment delay of > 4 weeks  will result in the
removal from study treatment.
Dosing may need to be interrupted for AEs considered not related to cabo zantinib if
this is clinically indicated or if causality is initially uncertain. Stu dy treatment may be
resumed at the same dose (or a lower dose per investigator judgment) if th eA E
is determined not to be related to cabozantinib once the investigator dete rmines that 
retreatment is clinically appropria te and the subject meets the protocol re-treatment 
criteria.
 
Table 4 General Approach to the Management of Study Treatment-Related Non-Hemat ologic Toxicities
CTCAE Version 4 Grade Guidelines/Intervention
Grade 1:Add supportive care as indicated. Continue study treatment at the  current dose
levels.
Grade 2:
Grade 2 AEs considered related to study treatment that are 
subjectively tolerable or easily 
managedAdd supportive care as indicated. Continue study treatment at the  current dose
levels.
Grade [ADDRESS_1101773] or 
deemed unacceptable in the investigatorâ€™s judgment; or are 
not easily managed or correctedxCabozantinib dosing should be interrupted until the AE resolves to Grade <1.  
8SRQUHVROXWLRQWREDVHOLQHRU*UDGHÂ”WUHDWPHQWPD\EHUHVX PHGDWHLWKHU
the same dose or with a dose reduction at the discretion of the  investigator 
unless this is a recurring event at which time the dose should be reduced.
Grade 3:
Protocol 2012-0252
November 11, 2016
Page 19
Grade 3 AEs considered related to 
study treatment which occurred 
without optimal prophylaxis or 
which is easily managed by [CONTACT_798762] (e.g., correction of electrolyt es) with 
UHVROXWLRQWREDVHOLQHRU*UDGHÂ”ZLWKLQKRXUVWUHDWPHQW PD\EHUHVXPHG
at either the same dose or with a  dose reduction at the discret ion of the 
investigator unless this is a recurring event at which time the  dose should be 
reduced
xFor AEs that require supportive care, the dose should be held w hile supportive 
care is initiated and optimized.  Then upon resolution of the A E to baseline or 
*UDGHÂ”WUHDWPHQWVKRXOGEHUHVWDUWHGZLWKDGRVHUHGXFWLRQ 1RWHLIWKH
investigator believes the likelihood of a reoccurrence of the s ame Grade [ADDRESS_1101774].
Grade 3 AEs considered related to 
study treatment that occurred 
despi[INVESTIGATOR_798741],QWHUUXSWVWXG\WUHDWPHQWXQWLOUHFRYHU\WRÂ”*UDGHRUEDVHOL QHDQGUHVXPH
treatment with a dose reduction
Grade 4:
Grade [ADDRESS_1101775] is 
XQHTXLYRFDOO\GHULYLQJFOLQLFDOEHQHILW,QWKLVFDVHXSRQUHF RYHU\WR*UDGHÂ”
or baseline, the subject may be re-treated at a reduced dose th at is to be 
determined by [CONTACT_093].
Dose reductions or delays may occur in the setting of lower grade toxicity than defined above if the 
investigator believes that it is in the interest of the subjectâ€™s safety.
 
 
Table 5 General Approach to the Management of Hematologic Toxicities
CTCAE Version 4 Grade Intervention
Neutropenia
Grade 3 neutropenia with documented 
infection
*UDGHQHXWURSHQLDÂ•GD\V
Grade 4 neutropenia,QWHUUXSWFDER]DQWLQLEWUHDWPHQWXQWLOUHVROXWLRQWR*UDGHÂ” 1, and resume 
cabozantinib treatment at a reduced dose.
Thrombocytopenia 
Grade 3 thrombocytopenia with 
clinically significant bleeding or Grade 4 
thrombocytopenia,QWHUUXSWFDER]DQWLQLEWUHDWPHQWXQWLOUHVROXWLRQWRÂ”*UDGH DQGUHVXPH
cabozantinib treatment at a reduced dose
Febrile Neutropenia
Grade 3 febrile neutropenia ,QWHUUXSWFDER]DQWLQLEWUHDWPHQWXQWLOUHFRYHU\RI$1&WR*UDGH Â”DQG
WHPSHUDWXUHWRÂ”Âƒ&DQGUHVX PHFDER]DQWLQLEWUHDWPHQWDWD UHGXFHG
dose.
Grade [ADDRESS_1101776] is unequivocally derivi ng clinical benefit. In this cas e, upon 
UHFRYHU\WR*UDGHÂ”RUEDVHOLQHWKHVXEMHFWPD\EHUH -treated at a 
reduced dose that is to be determined by [CONTACT_093].
Protocol 2012-0252
November 11, 2016
Page 20
x ANC, absolute neutrophil count; LLN, lower limit of normal
x1HXWURSHQLD*UDGH//1Â”$1&[9/L; Grade 2 (1 x 109/Â”$1&[9/L), Grade 3 (0.5 x 109/Â”$1&[9/L), Grade 
4 (ANC < 0.5 x 109/L).
x Febrile Neutropenia: Grade 3 (present); Grade 4 (Life-threatenin g consequences; urgent intervention indicated). 
x Thrombocytopenia: Grade 1 (<LLN â€“ 75 x 109/L); Grade 2 (<75.0 â€“ 50.0 x 109/*UDGH3ODWHOHWFRXQWÂ” - 25 x 109/L); Grade 4 
(Platelet count < 25 x 109/L).
 
7.1.[ADDRESS_1101777] signs of toxicity. G uidance for the management of fati gue, anorexia,
weight loss, non-gastrointestinal fistula, osteonecrosis of the jaw , eye disorders, 
musculoskeletal and connective ti ssue disorders, nervous system disor ders, 
respi[INVESTIGATOR_696]/thoracic/mediastinal disorders and congenital, familial and genetic 
disorders can be found in the Investigators Brochure.  
 
 
7.1.3 Diarrhea, Nausea, Vomiting, Stomatitis, and Mucositis
Diarrhea
Subjects should be instructed to notif y their physician and/or study nurs e 
immediately at the first signs of poorly formed or loose stool or an inc reased 
frequency of bowel movements. Administration of antidiarrheal agents is 
recommended at the first sign of diarrhea as initial management. Lopera mide is 
recommended as standard first line therapy. Alternatively, diphenoxyl ate/atropi[INVESTIGATOR_342844]. Additional agents to consider in subjects with diarrhea that is refractory
to the above include deodorized tincture of opi[INVESTIGATOR_342845]. Some su bjects
may require concomitant therapy with loperamide, diphenoxylate/atropi [INVESTIGATOR_050], and
deodorized tincture of opi[INVESTIGATOR_342846]. When combination ther apy with
antidiarrheal agents does not control the diarrhea to tolerable levels, a dose reduction
and/or dose interruption of cabozantinib should be implemented as des cribed in
Table 3. In addition, general supportive measures should be implement ed including
continuous oral hydration, correction of fluid and electrolyte abnorm alities, small
frequent meals, and stoppi[INVESTIGATOR_151947]- containing products, high fat mea ls and
alcohol.
 
Nausea and Vomiting
Anti-emetic agents along with supportiv e care are recommended as clinic ally 
appropriate at the first sign of naus ea and vomiting. A dose reductions and/or dose 
interruption of cabozantinib may be required as described in Table 3 if a ntiemetic 
treatment and/or prophylaxis alone is not adequate.
 
Agents classified as having a high therapeutic index (such as 5-HT3 re ceptor 
antagonists, or NK-1 receptor anta gonists) per ASCO or MASCC/ESMO g uidelines 
for anti-emetics in oncology or dexamethasone are recommended. Cautio ni s  
recommended with the use of aprepi[INVESTIGATOR_798742] a s cabozantinib
exposure may be affected by [CONTACT_798763] [INVESTIGATOR_798743] 2012-[ADDRESS_1101778] local treatments such as non- traumatic clean sing, and oral
rinses (eg, with a weak solution of salt and baking soda) should be maint ained. The
oral cavity should be rinsed and wipe d after meals, and dentures should be c leaned
and brushed often to remove plaque . Local treatment should be institute da tt h e
earliest onset of symptoms. When stomatitis interferes with adequate n utrition and
local therapy is not adequately effective, dose reduction or temporar y withholding of 
cabozantinib should be considered.
 
 
7.1.[ADDRESS_1101779] also been observed during treatment wi th 
cabozantinib. In general, it is recommended that subjects with elevatio no f  A L T ,  A S T ,  
and/or bilirubin have more frequent laboratory monitoring of these parameters. If
possible, hepatotoxic concomitant medications and alcohol should be discontinued in
subjects who develop elevated transaminases.
 
Since subjects may enter the study with elevations of AST/ALT at baseline , the 
following guideline should be used for dose modifications (Table 6):
Protocol 2012-[ADDRESS_1101780] at baseline
Grade 1 Continue study treatment with weekly monitoring of liver function tests (LFTs) for
at least [ADDRESS_1101781] weekly LFTs until reso lution to
GradHÂ”6W udy treatment may then be resumed at a one-dose-level reduction of 
cabozantinib
 
Grade [ADDRESS_1101782] twice weekly LFTs until
GradHÂ”2.  Then continue with at least weekly LFTs until resolution to Gr adeÂ”1. 
Study treatment may then be resumed at a one-dose-level reduction of
cabozantinib.
 
Grade [ADDRESS_1101783] 2-3 times per week, until resolution to Grade Â” If the subject 
was unequivocally deriving clinic al benefit, the subject may be a ble to resume
treatment at a lower dose as determined by [CONTACT_798764] 8/1EXWÂ”[ ULN (i.e., Grade 1) at  baseline
 
Â•.5 fold transaminases 
increase (at least one of AST 
or ALT) and still Grade [ADDRESS_1101784] weekly LFTs until resolution to Grad HÂ”1.  Study treatment may then be
resumed at a one-dose-level reduction of cabozantinib
 
Â•.5 fold transaminases 
increase (at least one of AST 
or ALT) and Grade 3Interrupt study treatment and monitor with at least twice weekly LFTs until
GradHÂ”2. Then continue with at least weekly LFTs until resolution to Grad eÂ”1. 
Study treatment may then be resumed at a one-dose-level reduction of
cabozantinib.
 
Grade [ADDRESS_1101785] 2-3 times per week, until resolution to Grade Â”,IWKH subject 
was unequivocally deriving clinical benefit, the subject may be able to resume
treatment at a lower dose as determined by [CONTACT_093].
 
Subjects  AST or ALT > 3.0 but Â”.[ADDRESS_1101786] at  baseline
 
Â•.5 fold transaminases 
increase (at least one of AST 
or ALT) and still Grade [ADDRESS_1101787] twice weekly LFTs until LFTs 
resolve to baseline and Grade Â”2.  Study treatment may then be resumed at a lower
dose as determined by [CONTACT_093].
Grade [ADDRESS_1101788] 2-3 times per week, until resolution to Grade Â”,IWKH subject 
was unequivocally deriving clinical benefit, the subject may be able to resume
treatment at a lower dose as determined by [CONTACT_093].
Protocol 2012-0252
November 11, 2016
Page 23
 
Cabozantinib treatment should also be i nterrupted when transaminase in creases are 
accompanied by [CONTACT_408251], and/or elev ations of 
coagulation tests (eg, International Normalized Ratio [INR]). Monitor ing of 
transaminases should be intensified (2â€“3 times per week) and cabozantin ibshould be
held until the etiology of the abnor malities is determined and these abno rmalities are
corrected or stabilize at clinically acceptable levels (INR < 1.[ADDRESS_1101789], total bilirubin
< 1.5uULN, aminotransferases < 2.[ADDRESS_1101790] or baseline).
 
Subjects must have cabozantini b permanently discontinued if tran saminase elevations 
are accompanied by [CONTACT_528930] (bilir ubin elevation
>2xULN), in the absence of evidenc e of biliary obstruction (i.e., significant elevation 
of alkaline phosphatase [ALP] ) or some other explanation of the  injury (e.g., viral
hepatitis, alcohol hepatitis), a s the combined finding (i.e., Hy â€™s Law cases) represents 
a signal of a potential for the drug to cause severe liver injur y.
 
All subjects who develop isolated b ilirubin elevations of Grade [ADDRESS_1101791] study 
treatment held until recovered to Grade Â”RUEDVHOLQH (or lower). If this occurs 
within [ADDRESS_1101792] not been associated with clinically apparent sequelae. It
is recommended that subjects with lipase elevation and/or symptoms of
pancreatitis have more frequent laboratory monitoring of lipase and/or amylase (2-3
times per week- see Tables 7 and 8). Subjects with symptomatic pancreatit is should 
be treated with standard supportive measures.
Protocol 2012-0252
November 11, 2016
Page 24
 
Table 7 Asymptomatic Lipase or Amylase Elevations
 
Asymptomatic Lipase or Amylase Elevations
Grade 1 or Grade 2 Continue at current dose level. More frequent m onitoring is recommended
Grade 3 xInterrupt treatment
xMonitor lipase and amylase twice weekly
xUpon resolution to Grade Â”or baseline, cabozantinib may be restarted at 
the same dose or at a reduced dose provided that this occurs withi n [ADDRESS_1101793] resolved to Grade Â”or
baseline and retreatment must be at a reduced dose.
Grade 4 xInterrupt treatment
xMonitor lipase and amylase twice weekly
xUpon resolution to Grade Â”or baseline and if resolution occurred within
[ADDRESS_1101794] resolved to Grade Â”RU baseline and
retreatment must be at a reduced dose.
Table 8 Symptomatic Pancreatitis
 
Pancreatitis
Grade 1 Continue at current dose level. More frequent monitoring o f lipase and amylase
and radiographically is recommended
Grade 2 xInterrupt treatment
xMonitor lipase and amylase twice weekly
xUpon resolution to Grade Â”or baseline , cabozantinib may be restarted 
at the same dose or at a reduced dose provided that this occurs within [ADDRESS_1101795] be interrupted again and 
till resolution to Grad HÂ” or baseline and retreatment must be at a 
reduced dose.
Grade 3 xInterrupt treatment
xMonitor lipase and amylase twice weekly
xUpon resolution to Grade Â”or baseline , cabozantinib may be restarted 
at a reduced dose if resolution occurred within [ADDRESS_1101796] was unequivocally
deriving benefit from cabozantinib therapy, treatment may resume at a reduced 
dose per investigator judgment.
Protocol 2012-0252
November 11, 2016
Page 25
 
7.1.6 Skin Disorders
 
Palmar-plantar erythrodysesthes ia syndrome (PPE; also known as hand- foot 
syndrome), skin rash (including blister, erythematous rash, macular r ash, skin 
exfoliation, dermatitis acneiform, a nd papular rash), pruritus, dry s kin, erythema, 
pi[INVESTIGATOR_9491], and alopecia have been reported with cabozantinib. A ll 
subjects on study should be advised on prophylactic measures including the use of 
emollients, removal of calluses, avoidance of exposure of hands and f eet to hot 
water leading to vasodilatation, protection of pressure-sensitive are as of hands and 
feet, and use of cotton gloves and socks to prevent injury and keep the pa lms and 
soles dry.
 
The onset of PPE is variable with pa resthesia (tingling, numbness) bei ng the 
characteristic initial manifestation, which can be accompanied by [CONTACT_798765]. PPE advances with symmetrical painful erythema and swollen 
areas (edema) on the palms and soles . The lateral sides of the fingers o r periungual 
zones may also be affected. Adequate in terventions are required to preven t
worsening of skin symptoms such a s blisters, desquamations, ulcerat ions, or 
necrosis of affected areas.
 
Aggressive management of symptoms is recommended, including early 
dermatology referral (Table 9). Subj ects with skin disorders should be carefully 
monitored for signs of infection (eg, abscess, cellulitis, or impeti go). In the case of 
study treatment-related skin chang es (eg, rash, hand-foot syndrome), t he 
investigator may request that add itional assessments be conducted with t he 
subjectâ€™s consent. These assessments may include digital photographs of  the skin 
changes and/or a biopsy of the affected skin and may be repeated until the s kin 
changes resolve.
Table 9 Management of Hand-Foot Syndrome
Hand-Foot Skin Reaction and Hand Foot Syndrome (PPE)
No apparent toxicity Prophylaxis with Ammonium lactate 12% cream (Amlactin Â®) twice daily OR
heavy moisturizer (e.g. Vaseline) twice daily
Grade 1 Continue treatment at current dose if tolerable or reduce to t he next lower dose if 
intolerable. Start urea 20% cream twice daily AND clobetasol 0.05 % cream once 
daily. Assess subject at least weekly for changes in severity. Subje cts should be 
instructed to notify investigator immediately if severity worsens . If severity 
worsens at any time or if there is no improvement after 2 weeks, proce ed to the
management guidelines for Grade 2 PPE
Grade 2 Reduce study treatment to next lower level and/or interrupt  dosing. Start/continue 
urea 20% cream twice daily AND clobetasol 0.05% cream once daily. Pa in control
with NSAIDs/GABA agonists/narcotics. Assess subject at least weekly f or changes 
in severity. Subjects should be instructed to notify investigator i mmediately if 
severity worsens.  If severity worsens at any time (eg, peeling, bl isters, bleeding,
edema, or hyperkeratosis or affects self-care) or if there is no impro vement after 2
weeks, proceed to the management guidelines for Grade 3 PPE.  If the dos ew a s  
reduced, then upon resolution to Grade 0 or Grade 1, treatment may conti nue at the
reduced dose.  If the dose was only interrupted but not reduced, then treatment may
be restarted at one dose level lower.
Protocol 2012-0252
November 11, 2016
Page 26
Grade 3 Interrupt study treatment un til severity decreases to Grade 1  or 0.  Start/continue
urea 20% cream twice daily AND clobetasol 0.05% cream once daily. Pa in control
with NSAIDs/GABA agonists/narcotics. Treatment may restart at one dose level 
lower when reaction decreases to Grade [ADDRESS_1101797]
from study if reactions worsen or do not improve within 6 weeks.
GABA,È–-aminobutyric acid; NSAID, nonsteroidal anti-inflammatory drugs; PPE , palmar-plantar erythrodysesthesia
 
 
7.1.7 Embolism and Thrombosis
In clinical studies with cabozantinib, venous thrombotic events (DVT a nd PE) have 
been observed in less than 10% of subjects, and arterial thromboemboli c events (MI 
and TIA) have been reported rarely. In addition, subjects with cancer ha ve a
significantly increased likelihood of developi[INVESTIGATOR_798744].
 
Subjects who develop a PE and/or DVT should have study treatment interru pted 
until full anticoagulation is established with low molecular weight heparin 
(LMWH) or Coumadin. Anticoagu lation with LMWH is preferred over 
Coumadin if possible and feasib le. Venous filters (e.g. vena cava f ilters) are not
recommended due to the high incidence of complications associated with their use.
Once a subject is fully anticoagulated, treatment can be restarted per inv estigator
judgment at one dose lower. Subject s should permanently discontinue af ter a
second thrombotic event. Although r outine prophylactic  anticoagulati on is not
necessary for all subjects, prophylactic anticoagulation is allowed f or individual
subjects at the discretion of the investigator.
 
Cabozantinib should be discontinued in subjects who develop an acute MI or any 
other clinically significant arterial thromboembolic complication.
 
 
7.1.[ADDRESS_1101798] measurement. Other th an for 
hypertension requiring immediate the rapy, the presence of new or wors ened 
hypertension should be confirmed at a second visit before taking new ther apeutic 
action. Blood pressure should be monitored in a constant position visit t o visit, 
either sitting or supi[INVESTIGATOR_050]. Cabozantinib dosing should be interrupted in s ubjects with 
severe hypertension (180 mm Hg systolic or 120 mm Hg diastolic; or su stained
Â•PP Hg systolic RUÂ•GLDVWROLF who cannot be controlled with medical 
interventions and discontinued in s ubjects with hypertensive crises or hypertensive 
encephalopathy (Table 10).
Protocol 2012-0252
November 11, 2016
Page 27
 
Table 10 Management of Hyperten sion Related to Cabozantinib
 
Criteria for Dose Modifications Treatment/cabozantinib Dose Modifi cation
 
Subjects not receiving optimized anti-hypertensive therapy
 
> 140 mm Hg (systolic) and < 160 mm Hg
OR
> 90 mm Hg (diastolic) and < 110 mm Hg
 
 
  
 
 
Â•160 mm Hg (systolic) and < 180 mm Hg
OR
Â•10 mm Hg (diastolic) and < 120 mm Hg
 
 
  
 
  
 
Â•180 mm Hg (systolic) OR
Â•20 mm Hg (diastolic )xIncrease antihypertension the rapy (i.e., increase dose of 
existing medications and/or add new antihypertensive
medications)
xMaintain dose of cabozantinib
xIf optimal antihypertensive therapy (usually to include
3 agents) does not result in blood pressure < 140 systolic or <
90 diastolic, dose of cabozantinib should be reduced.
xReduce cabozantinib by [CONTACT_30560].
xIncrease antihypertension therapy (i.e., increase dose of 
existing medications and/or add new antihypertensivemedications)
xMonitor subject closely for hypotension.
xIf optimal antihypertensive therapy (usually to include
3 agents) does not result in blood pressure < 140 systolic or <
90 diastolic, dose of cabozantinib should be reduced further.
 
xInterrupt treatment with cabozantinib Add new or additional 
anti-hypertensive medications and/or increase dose of existing 
medications.
xMonitor subject closely for hypotension.
xWhen SBP < 140 and DBP < 90, restart cabozantinib treatment 
at one dose level lower
xIf optimal antihypertensive therapy (usually to include
3 agents) does not result in blood pressure < 140 systolic or <
90 diastolic, dose of cabozantinib should be reduced further.
BP, blood pressure, SBP systolic blood pressure, DBP diastolic blood pre ssure
NOTE: If SBP and DBP meet different criteria in table, manage per higher do se-modification criteria
 
 
7.1.9 Proteinuria
 
Proteinuria has been reported with a pproved drugs that inhibit VEGF pa thways as 
well as with cabozantinib. Development and worsening of proteinuria s hould be 
monitored by [CONTACT_716138] (qualitative/semiquantitative assessment by [CONTACT_5230]; 
quantitative assessment by [CONTACT_39701]/urine creatinine ratio [UPCR ], or 24-hour 
urine protein excretion). When a UPCR exceeds 1 (mg/dL protein / mg/dL creatinine), a repeat UPCR or a 24-hour  urine protein and creatinine sh ould be 
performed to confirm the result. Caboz antinib should be discontinued in s ubjects
who develop nephrotic syndrome (prot einuria > 3.5 grams per day in combi nation
Protocol 2012-0252
November 11, 2016
Page 28
 
with low blood protein levels, high c holesterol levels, high triglyceri de levels, and 
edema) or any other relevant renal di sease. Also, given the nephrotoxic potential of 
bisphosphonates, these agents should be used with caution in patients rec eiving 
treatment with cabozantinib. Details of management are described in Tab le 11.
 
 
Table 11 Management of Treatment Emergent Proteinuria
 
Urine Protein/Creatinine Ratio Action To Be Taken
Â” xNo change in treatment or monitoring
>1a n d<3 . 5 xConfirm with a 24 hour urine protein excretion within 7 days
xIf proteinuria of > 1 g/24 hours is confirmed, hold cabozantinib and
continue with UPCR monitoring. When UPCR returns to < 1,
restart cabozantinib at a reduced dose. Continue monitoring UPCRonce every week until two consecutive readings are < 1, then revert 
to UPCR monitoring frequency specified in the protocol.
Â•3.[ADDRESS_1101799] for 
resolution of nephrotic syndrome.
xIf proteinuria of Â• g/24 hours is confirmed without diagnosis of 
nephrotic syndrome, continue to hold cabozantinib and monitor
UPCR weekly. If UPCR decreases to < 1, restart cabozantinib at a 
reduced dose. Continue monitoring UPCR once every week until 
two consecutive readings are < 1, then revert to UPCR monitoring 
frequency specified in the protocol.
UPCR, urine protein/urine creatinine r atio
 
7.1.[ADDRESS_1101800] s should be 
evaluated for potential bleeding ris k factors prior to initiating cabo zantinib 
treatment and monitored for bleeding events with serial complete blood c ounts and 
physical examination while on study. Risk factors for hemorrhagic even ts may 
include (but may not be limited to) the following:
 
 
xTumor lesions of the lung with cavita tions or tumor lesions which invade,  
encase, or abut any major blood vessels; non-small cell lung cancer (NSCL C) 
with squamous cell differentiatio n is known for significant lung cavi tations and 
centrally located tumors that may invade major blood vessels. The anatom ic 
location and characteristics of tumor as well as the medical history sho uld be 
carefully reviewed in the selection of subjects for treatment with caboz antinib.
Protocol 2012-[ADDRESS_1101801] normal hemostasis (eg, defic iencies 
in clotting factors and/or platelet function, or thrombocytopenia)
xConcomitant medication with anticoagu lants or other drugs which affect normal 
hemostasis
 
Based on the described predisposing risk factors for hemoptysis, many studies with 
antiangiogenic drugs exclude subjects with NSCLC and squamous cell differentiation. Although enrollment of subjects with NSCLC with squa mous cell 
differentiation has been allowed on cabozantinib studies, cabozantin ib studies 
exclude NSCLC subjects with any of the following: tumors abutting, enca sing, or 
invading a major blood vessel; cavitating lesions; history of clinicall y significant 
hemoptysis; or recent (within 3 months) radiation therapy to the thoraci cc a v i t y  
including brachytherapy unless radiation therapy targets bone metasta sis.
 
Cabozantinib should be discontinue d in subjects with serious and life-t hreatening 
bleeding events or recent hemoptysis Â•WHDVSRRQ (2.5ml) of red blood). 
Treatment with cabozantinib should be interrupted if less severe forms o f clinically 
significant hemorrhage occur and may be restarted after the cause of hemo rrhage 
has been identified and the risk of  bleeding has subsided. Therapy of  bleeding 
events should include supportive care and standard medical intervention s.
 
Furthermore, subjects who develop tumors abutting, encasing, or invad ing a major 
blood vessel or who develop cavitation of their pulmonary tumors while on study 
treatment must be discontinued from cabozantinib treatment.
 
 
7.1.[ADDRESS_1101802].
 
 
7.1.12  Guidelines for Prevention of GI Perforation/Fistula and Non -GI Fistula Formation
GI perforation/fistula and Non-GI f istula formation have been reporte d with 
approved drugs that inhibit VEGF pathways as well as with cabozantini b. Carefully 
monitor for epi[INVESTIGATOR_151949], especially in subjects with kno wn risk 
factors for developi[INVESTIGATOR_798745]/fistula or non-GI fistula, to allow for early 
diagnosis. Such risk factors include (but may not be limited to) the follo wing:
Protocol 2012-0252
November 11, 2016
Page 30
 
GI-perforation/fistula:
xIntra-abdominal tumor/metastases invading GI mucosa
xActive peptic ulcer disease, inflammatory bowel disease, ulcerative col itis,
diverticulitis, cholecystitis or symptomatic cholangitis, or append icitis
xHistory of abdominal fistula, GI perforation, bowel obstruction, or 
intra- abdominal abscess
xPrior GI surgery (particularly wh en associated with delayed or inco mplete 
healing). Complete healing following abdominal surgery or resolution of 
intra-abdominal abscess must be c onfirmed prior to initiating treatmen tw i t h  
cabozantinib.
 
 
Additional risk factors include conc urrent chronic use of steroid tre atment or
non-steroidal anti-inflammatory drugs. Constipation indicative of bo wel obstruction 
should be monitored and effectively managed.
 
Non-GI fistula:
xRadiation therapy has been identif ied as a possible predisposing risk f actor
for non-GI fistula formation in subjects undergoing treatment with suc h 
agents (eg, bevacizumab). Radiation therapy to the thoracic cavity (including 
mediastinum) should be avoided within [ADDRESS_1101803] been diagnosed with GI or 
non-GI perforation/fistula.
 
 
7.1.[ADDRESS_1101804] 3 weeks (5 half lives) prior to elective surge ry.
 
Protocol 2012-0252
November 11, 2016
Page 31
7.1.14  Endocrine Disorders
 
Prospective studies of markers of t hyroid functions are currently ongo ing in two 
single-agent studies to characterize the effects of cabozantinib on th yroid function. 
Preliminary data indicate that cabozantinib affects thyroid function te sts (TFTs) in a
high number of subjects. In Study XL184-203, 17 of 34 (50%) euthyro id subjects 
with castration-resistant prostat e cancer (CRPC) developed abnormal t hyroid-
stimulating hormone (TSH) levels 6 weeks after initiation of cabozanti nib treatment 
(6% showed TSH levels between 5 and 7 mU/L, 44% had TSH > 7 mU/L). The median TSH level at week 6 was 5.2 mU/L (range, 0.02-29.7 mU/L). In a P hase 1 
combination study of rosiglitazone and cabozantinib (XL184-008) to de termine the 
potential for a clinically significant drug-drug interaction of cabo zantinib on
the 
CYP isozyme CYP2C8, subjects with advanced solid tumors (particularly renal cell 
carcinoma [RCC] and differentiated thyroid cancer [DTC]) are enrolled. Among 11 
evaluable subjects, the AE of hypothy roidism was reported in 55% of su bjects. 
Currently available data are insufficient to determine the cause of TFT alterations 
andits clinical relevance. Routine monitoring of thyroid function and asse ssments 
for signs and symptoms associated with thyroid dysfunction is recommen ded for 
subjects treated with cabozantinib. Management of thyroid dysfunction (eg,
symptomatic hypothyroidism) should follow accepted clinical practice guidelines.
 
Other endocrine disorders such as hypocalcemia and hyperglycemia, an d associated 
laboratory changes, have been observed in less than 10% of subjects. Mo nitoring 
with standard laboratory tests for endocrine disorders and clinical exa mination prior 
to initiation and during treatment with cabozantinib is recommended. Cab ozantinib 
should be discontinued in subjects with severe or life-threatening endo crine 
dysfunction.
 
 
7.1.15  Guidelines for Prevention of Osteonecrosis of the Jaw
Osteonecrosis of the jaw (ONJ) has  been reported with use of antiangio genic
drugs and bisphosphonates and denosum ab in cancer patients. Additional risk 
factors for ONJ have been identifie d such as use of corticosteroids , chemotherapy,
local radiotherapy, poor oral hygiene, smoking, dental or orofacial su rgery 
procedures, and cancer disease itself. Three cases of osteonecrosis hav eb e e n
reported in subjects treated with cabozantinib, the details of which are provided in
the current version of IB. As a preventive measure, invasive dental pr ocedures
should be avoided if possible in subj ects who have previously been treat ed with or 
concomitantly receive bisphosphonates or denosumab. In cases where de ntal 
procedures are unavoidable, the risks  and benefits of a dental procedur ea n dt h e  
extent of the procedure as well as t he risk of developi[INVESTIGATOR_798746] f  t h ej a w  
need to be considered when deciding on the duration of a temporary treatm ent 
interruption of cabozantinib. If clinically possible, treatment with c abozantinib 
should be held for at least [ADDRESS_1101805] be discusse d with and approved by [CONTACT_17190] a case by 
[CONTACT_413].
 
 
7.2 Potential Drug Interactions
Cytochrome P450: Preliminary data from a clinical drug interaction stud y( S t u d y  
XL184-008) show that clinically relevant steady-state concentration so f  
cabozantinib appear to have no marked effect on the AUC of co-administ ered
rosiglitazone, a CYP2C8 substrate. Therefore, cabozantinib is not ant icipated to
markedly inhibit CYP2C8 in the clinic, and by [CONTACT_151998], is not anticip ated to
markedly inhibit other CYP450 isozy mes that have lower [I]/Ki values co mpared to
CYP2C8 (ie, CYP2C9, CYP2C19, CYP 2D6, CYP1A2, and CYP3A4). In vitro
data indicate that cabozantinib is unlikely to induce cytochrome P450 enzymes,
except for possible induction of CYP1A1 at high cabozantinib concent rations (30
È0
 
Cabozantinib is a CYP3A4 substrate (but not a CYP2C9 or CYP2D6 substra te),
based on data from in vitro studies usin g CYP-isozyme specific neutrali zing
antibodies. Preliminary results from a clinical pharmacology study, XL 184-006,
showed that concurrent administ ration of cabozantinib with the stron g CYP3A4 
inducer, rifampin, resulted in an appr oximately 80% reduction in caboz antinib
exposure (AUC values) after a single dose of cabozantinib in healthy vo lunteers. Co-
administration of cabozantinib with strong inducers of the CYP3A4 fa mily (eg,
dexamethasone, phenytoin, carbamaze pi[INVESTIGATOR_050], rifampin, rifabutin, rifap entin,
phenobarbital, and St.Johnâ€™s Wort) may significantly decrease cabozantinib
concentrations. The chronic use of strong CYP3A4 inducers should be avo ided.
Other drugs that induce CYP3A4 should be used with caution because thes ed r u g s  
have the potential to decrease exposure (AUC) to cabozantinib. Selecti on of 
alternate concomitant medications with no or minimal CYP3A4 enzyme i nduction
potential is recommended. In addition, caution must be used when disco ntinuing
treatment with a strong CYP3A4 inducer in asubject who has been concurrently
receiving a stable dose of cabozantinib, as this could significantly i ncrease the
exposure to cabozantinib.
 
Preliminary results from a clinical pharmacology study, XL184-007, sho wed that 
concurrent administration of caboz antinib with the strong CYP3A4 inh ibitor, 
ketoconazole, resulted in a 33-39% i ncrease in the cabozantinib exposur e( A U C  
values) after a single dose of cabozantinib in healthy volunteers. Co-ad ministration
of cabozantinib with strong inhibitors of the CYP3A4 family (eg, ketoc onazole, 
itraconazole, clarithromycin, indi navir, nefazodone, nelfinavir, and ritonavir) may 
increase cabozantinib concentrations. Grapefruit / grapefruit juice an d Seville
oranges may also increase plasma concentrations of cabozantinib. Stron g CYP3A4 
inhibitors and other drugs that i nhibit CYP3A4 should be used with cau tion because
these drugs have the potential to increase exposure (AUC) to cabozantin ib. Selection
of alternate concomitant medicati ons with no or minimal CYP3A4 enzy me
inhibition potential is recommended.
 
Protocol 2012-0252
November 11, 2016
Page 33
Because in vitro studies only assessed the metabolizing capacity of theCYP3A4, CYP2C9, and CYP2D6 pathwa ys, the potential for drugs that
inhibit/induce other CYP450 pathways (eg, CYP2C8, CYP2C19, CYP2B6, CYP1A2) to alter cabozantinib expos ure is not known. Therefore, these drugs 
should be used with caution when given with cabozantinib.
As warfarin is metabolized thr ough the CYP450 system, therapeut ic anticoagulation 
with warfarin (eg, Coumadin) is not recommended. As an alternat ive, therapeutic 
anticoagulation may be accomplishe d using low-molecular weight heparin (eg, 
Lovenox) or heparin. 
 However, Cabozantinib und ergoes only minor CYP2C9 
metabolism and does not inhibit CYP2C9. Thus, there is no speci fic drug-drug 
contraindication and Coumadin can be utilized in select patient s if LMWH is not 
feasible.  
Please refer to the Flockhart drug interaction tables for lists of subs trates,
inducers, and inhibitors of select ed CYP450 isozyme pathways (Flockh art 2007; 
http://medicine.iupui.edu/ clinpharm/ddis/table.aspx ).
 
Protein Binding: Cabozantinib is highly protein bound (approximately 9 9.9%) to 
human plasma proteins. Therefore, highly protein bound drugs should be used with 
caution with cabozantinib because there is a potential displacement inte raction that 
could increase free concentrations of cabozantinib and/or a co-administ ered highly 
protein-bound drug (and a corresponding increase in pharmacologic effe ct). Factors 
that influence plasma protein binding may affect individual tolerance tocabozantinib. Therefore, concomitant medications that are highly prot ein bound (eg,
diazepam, furosemide, dicloxacillin, and propranolol) should be used with caution.
Because warfarin is a highly protein bound drug with a low therapeutic i ndex,
administration of warfarin at ther apeutic doses should be avoided in su bjects
receiving cabozantinib due to the poten tial for a protein binding displ acement
interaction.
 
Other Interactions: In a relative bioavailability study in dogs cabozantinib exposure
was not significantly affected by d rugs that alter gastric pH. Never theless, drugs such 
as proton pump inhibitors (PPIs) and H 2-antagonists produce profound suppression of 
gastric acid secretion and significant increases in gastric pH. By [CONTACT_798766], 
PPIs and H 2-antagonists may decrease cabozantin ib plasma exposure levels and its 
effectiveness in vivo, resulting in clinically significant drug intera ctions. The use of 
PPIs (eg, omeprazole, lansoprazole, rabeprazole, pantoprazole, and es omeprazole) 
and/or H 2-antagonists (eg, ranitidine, famotidine, and nizatidine) is discourag ed 
during this study. If antacids are not adequate, the use of H 2blockers is preferred over 
PPIs (Note: Cimetidine should be avoi ded because of its potential to int erfere with 
CYP3A4 mediated metabolism of cabozantinib). Antacids, H 2blockers, or PPIs 
should be taken at least 2 hours (preferably 4 hours) after taking cabozantin ib but at 
least [ADDRESS_1101806] that cabozantinib is unlikely to be a substrate for  P 
glycoprotein (P-gp), but it does a ppear to have the potential to inhibi t the P-gp 
transport activity. Additional details related to these overall conclu sions are
provided in the Investigators Brochure.
 
Protocol 2012-[ADDRESS_1101807] up toand including follow-up visits will be reported. Safety will be
evaluated for all treated patient s using the NCI CTCAE version 4.0
(http://ctep.cancer.gov). Safety assessments will be based on medical review of AE 
reports and the results of vital sign measurements, physical examinations and
clinical laboratory tests.
 
8.[ADDRESS_1101808] 
tumor measurements (if applicable) and document them on standard MDACC forms in the medical record.
 
 
9.0 Statistical Methods
 
Objectives and Sample Size: This is a phase II study of cabozantinib in pa tients with 
previously untreated androgen-dep endent disease. The primary objectiv e is to assess 
progression-free survival (PFS). W e will assess response and overall s urvival as 
secondary endpoints. A maximum of 60 pa tients will be entered into this trial, at an
expected accrual rate of 2-3 patient s per month. The trial will require approximately 24
months for patient accrual and an a dditional 9 months for patient follo w-up. If the trial
continues to maximum accrual and maintains sufficient follow-up to obse rve 49
progression events with a median P FS of 11.2 months, then a 95% credi ble interval for 
median PFS would extend from 8.5 t o 14.9 months. Based on historical m ean survival
time 11.2 months, a mean progression-free survival time on average > 13 m onths would 
be considered promising evidence of anti- disease activity.
 
Design and Interim Analysis: This is phase II study and a Bayesian model wi ll be used to 
monitor the trial with a recommendation to stop the trial if the PFS is wors e than historical 
data. In particular, we assume that time to progression T follows an ex ponential
distribution with mean Î¼ and Î¼* = median (T) = Î¼log(2). The trial will be stopped if Pr (Î¼* 
<Î¼ H* | data) > 0.95, where Î¼ H* is the median PFS with an inverse gamma distribution
IG(22.07, 235.99), which corresponds to a 95%CI of  (7.3, 17.0) based on the historical
data (Millikan, et al., 2008). The prior for Î¼* is assumed to be IG(a, b ), where the
parameters a =3.25 and b = 25.25 is determined based on PFS with the sam e mean (11.2 
months) and a larger standard deviation of 10.  Assuming an accrual rat e of 2.5 per month,
the operating characteristics for t he futility stoppi[INVESTIGATOR_798747], with results based on 1000 simulati ons.
 
Protocol 2012-0252
November 11, 2016
Page 35
Median PFS Prob(Stop Early) Mean No. of Patients
(25%, 75%)
13.2 months 0.019 59.2 (60, 60)
11.2 months 0.072 57.4 (60, 60)
9.2 months 0.246 52.2 (60, 60)
7.2 months 0.700 40.5 (24, 60)
6.2 months 0.924 31.2 (17, 44)
A Bayesian sequential monitoring method (Thall, 1995) will be used to m onitor for any study 
treatment related Grade 4 toxic ity that fails to resolve to <Gr ade 2 within 14 days after the 
cabozantinib is held.
We stop the trial if the toxicity is likely to be greater than 30%. That is, s top the trial if
 
Prob{toxicity rate > 30% | data} > 0.85.
 
The prior distribution of toxicity rate is assumed to be beta (1, 1).  Fol lowing this rule, the 
trial will be terminated due to toxicity if [# toxicity]/[# patients eval uated]Â• 9/20, 
12/30, 15/40, 19/50, or 22/60. The operating characteristics table is given in the following table, 
based on 1000 simulations:
 
true Prob(tox) Pr(stop) mean # Pts (median)
0.1 0.001 59.9 (60)
0.2 0.04 58.0 (60)
0.3 0.32 47.7 (60)
0.4 0.79 29.2 (20)
0.5 0.98 16.9 (10)
 
 
The trial will be conducted through t he Clinical Trial Conduct website 
(https://biostatistics.mdanderson.org/ClinicalTrialConduct), which is hosted on a secure 
server at MDACC and maintained by [CONTACT_798767] s. Access to 
the website will be gained through usernames and passwords provided by [CONTACT_798768]. Trainin g on the use of the Clinical Trial Cond uct website will be 
provided by [CONTACT_798769] y initiation.
 
Demographic and baseline laboratory r esults will be summarized using des criptive statistics, 
including means with standard deviations, or medians with ranges, histog rams and box-plot. 
Survival or times to failure and time-to-progression functions will be e stimated using the 
Kaplan-Meier method. Failure will be classified as: Death due to prostate cancer or unknown 
cause; disease progression, need for palliative radiation to more than [ADDRESS_1101809] toxicity grades per patient will be tabulated for selected advers e events and laboratory
measurements.  
 
Protocol 2012-0252
November 11, 2016
Page 36
10.0  DATA AND PROTOCOL MANAGEMENT
 
10.1  Registration Procedure and Data Reporting
All data will be entered to the Department of Genitourinary Medical Oncol ogy
Oracle database (GURU).  GURU is a p assword protected database with a n audit
trail. Data can be collated with a unique GURU identification in order to de-link
information. The minimum required fields will be entered to the MDACC req uired 
data collection systems (CORe/PDMS). Registration data entry will occu r prior to 
initiation of therapy. All eligibility criteria must be satisfied. Repo rting to the 
supporting agency will follow the contract agreement.
 
10.[ADDRESS_1101810] patient is enrolled in the study.
 
 
11.0  SAFETY AND ADVERSE EVENT REPORTING
 
11.1  Reporting Requirements
 
11.1.1  Adverse Drug Reaction Reporting
Toxicity will be scored using CTC Version 4.0 for toxicity and adverse e vent 
reporting. A copy of the CTC Version 4.0 can be downloaded from the CTEP homepage ( http://ctep.info.nih.gov ). All appropriate treatment areas have
access to a copy of the CTC Version 4.0.
 
Adverse events will for this protoc ol will be documented and entered int ot h ec a s e
report form according the Recommended A dverse event Recording Guideline s for 
Phase II protocol.
 
 
Table 12.
Recommended Adverse Event Recording Guidelines
 
AttributionGrade 1 Grade 2 Grade 3 Grade 4 Grade 5
      
 
Unrelated 
Phase I 
Phase I 
Phase I
Phase II Phase I
Phase II
Phase IIIPhase I
Phase II
Phase III
 
Unlikely 
Phase I 
Phase I 
Phase IPhase II Phase IPhase II
Phase IIIPhase I
Phase II
Phase III
 
Possible 
Phase I
Phase IIPhase I
Phase II
Phase IIIPhase I
Phase II
Phase III Phase I
Phase II
Phase IIIPhase I
Phase II
Phase III
Probable Phase I Phase I Phase I  Phase I Phase I
Protocol 2012-0252
November 11, 2016
Page 37
 
 Phase II Phase II
Phase IIIPhase II
Phase III Phase IIPhase IIIPhase II
Phase III
 
Definitive 
Phase I
Phase IIPhase I
Phase IIPhase IIIPhase I
Phase IIPhase III Phase IPhase IIPhase IIIPhase I
Phase IIPhase III
 
The Investigator or physician designee is responsible for verifying an d providing 
source documentation for all adverse e vents and assigning the attributi on for each 
event for all subjects enrolled on the trial.
 
11.1.2 Serious Adverse Event Reporting (SAE)
 
An adverse event or suspected advers e reaction is considered â€œseriousâ€ i f ,i nt h e  
view of either the investigator or the sponsor, it results in any of the following 
outcomes:
 
xDeath
xA life-threatening adverse drug experience â€“ any adverse experience that 
places the patient, in the view of the initia l reporter, at immediate risk of de ath 
from the adverse experience as it occurred. It does not include an advers e 
experience that, had it occurred in a more severe form, might have caused 
death.
xInpatient hospi[INVESTIGATOR_798748] t he ability to 
conduct normal life functions.
xA congenital anomaly/birth defect.
 
Important medical events that may not result in death, be life-threatenin g, or require 
hospi[INVESTIGATOR_3767] a serious adverse drug experience whe n, based 
upon appropriate medical judgment, the y may jeopardize the patient or s ubject and 
may require medical or surgical inter vention to prevent one of the outcom es listed in
this definition. Examples of such medical events include allergic bron chospasm 
requiring intensive treatment in an emergency room or at home, blood dysc rasias or 
convulsions that do not result in inpatie nt hospi[INVESTIGATOR_059], or the dev elopment of drug 
dependency or drug abuse (21 CFR 312.32).
 
xImportant medical events as defined above, may also be considered seriou s 
adverse events. Any important medical event can and should be reported as  an 
SAE if deemed appropriate by [CONTACT_798770], 
IND Office.
xAll events occurring during the conduct of a protocol and meeting the 
definition of a SAE must be reported to the IRB in accordance with the 
timeframes and procedures outlined in â€œThe University of [LOCATION_007] M. D. 
Anderson Cancer Center Institutional Review Board Policy for Investig ators 
on Reporting Serious Unanticipated Adverse Events for Drugs and Dev icesâ€. 
Unless stated otherwise in the prot ocol, all SAEs, expected or unexpec ted, 
must be reported to the IND Office, regardless of attribution (within 5
working days of knowledge of the event).
Protocol 2012-[ADDRESS_1101811] a written report submitted within 24 hours (nextworking day) of knowledge of the event to the Safety Project Manager in t he 
IND Office.
xUnless otherwise noted, the electr onic SAE application (eSAE) will be  
utilized for safety reporting to the IND Office and MDACC IRB.
xSerious adverse events will be captured from the time of the first protoco l-
specific intervention, until [ADDRESS_1101812] be reported to the INDOffice. This may include the development of a secondary malignancy.
 
Reporting to FDA:
 
xSerious adverse events will be forwar ded to FDA by [CONTACT_9533] (Sa fety
Project Manager IND Office) according to 21 CFR 312.32.
 
It is the responsibility of the PI [INVESTIGATOR_798749] g to the Code of Federal Regulat ions, 
Good Clinical Practices, the protoc ol guidelines, the sponsorâ€™s guid elines, and 
Institutional Review Board policy.
 
Investigator Communication  with Supporting Companies:
 
As soon as an investigator becomes aware of an AE that meets the defini tion of
â€˜serious,â€™ this should be documented to the extent that information is av ailable.
 
xThis report must be submitted by [CONTACT_798771], even if it is not felt to be drug related. Email:  
[EMAIL_131] ;Fax [PHONE_154]
xThe investigator agrees to provide supplementary information requested by [CONTACT_798772].
xPregnancy, although not itself an SAE , should also be reported on an SAE form
or pregnancy form and be followed up to determine outcome, including 
spontaneous or voluntary terminati on, details of birth, and the presen ce or 
absence of any birth defects or congenital abnormalities.
 
Regulatory Reporting:
 
All serious unexpected adverse drug reactions (unexpected related SAE s) must be 
reported to the Food and Drug Adminis tration (FDA) by [CONTACT_798773] 21 CFR 312.32.
 
xThese reports are to be filed utilizing the Form FDA 3500A (MedWatch Form )o r  
the MDACC SAE form.
The final MedWatch or MDACC Form must be submitted by [CONTACT_798774] 2012-0252
November 11, 2016
Page 39
Exelixis within one to two business days of submission to the FDA to all ow 
Exelixis time to cross-report to Exelixisâ€™ IND. Email: [EMAIL_131] ;
Fax [PHONE_154]
 
 
11.2  Clinical Laboratory Adverse Events
 
The results of all laboratory tests required by [CONTACT_798775]â€™s medical record. All clinically important abnormal laboratory tests occurring 
during the study will be repeated at appropriate intervals until they retu rn either to 
baseline or to a level deemed acceptable by [CONTACT_798776].
 
The criteria for determining whether an abnormal laboratory test result should be 
reported as an adverse event are as follows:
 
1.   Test result is associated with accompanying symptoms, and/or2.   Test result requires additional diagnostic testing or medical/su rgical intervention, 
and/or
3.   Test result leads to a change in study dosing or discontinuation fro m the study, 
significant additional concomitant dr ug treatment or other therapy, an d/or
4.   Test result leads to any of the outcomes included in the definition of  a SAE, 
and/or
5.   Test result is considered to be an adverse event by [CONTACT_093].
 
*Merely repeating an abnormal test, in the absence of any of the above con ditions, 
does not meet Condition [ADDRESS_1101813] result that is determined to be an error does not requir e reporting 
as an adverse event, even if it did meet one of the above conditions except for 
Condition 4.
 
 
11.3  Management of Persistent and Refractory Toxicity
 
Utilizing the NCI CTCAE (version 4.0) , events which are moderate and int erfere with 
function that are not consistent with a patientâ€™s medical history, and are refractory to 
medical treatment, should be investig ated carefully to ensure that no ot her etiology is 
present. Study drug will be held for any toxicity events deemed definite ly,probably, 
or possibly drug-related (such as diarrhea, hypertension, vomiting, diarrhea, and 
dizziness) and that are greater than grade 2.  Drug will be held until sev erity is reduced
to Grade 1 or less and then resumed daily dosing with a dose reduction as  outlined in
Section 6.0.
 
 
11.4  Management of All Other Toxicities
 
Other toxicities may occur. Supportive care should be prescribed as need ed. They 
may also be prescribed prophylactically to prevent toxicity from develop ing or 
Protocol 2012-0252
November 11, 2016
Page 40
recurring. The examples include anti-emetics for nausea/vomiting, ana lgesics for 
pain, antipyretics for fever and antidiarrheals for diarrhea
 
Abnormal laboratory values will be onl y be captured as adverse events if t hey are
Grade [ADDRESS_1101814] management (eg, dose reduction or delay or requirement for additional
medication or 
monitoring) or that is considered to be of clinical significance by [CONTACT_798777].
 
11.5.2  Medication Errors/ Overdose
Any study drug administration error or overdose that results in an AE, even if it
does not meet the definition of serious, requires reporting within [ADDRESS_1101815] be
followed until either resolution of the event or determination by [CONTACT_798778]. This follow-up guidance als o applies to 
related SAEs that occur > [ADDRESS_1101816] dose of study treatment. The status 
of all other continuing AEs will be documented as of 30 days after the las t dose of 
study treatment.
 
12.0  PUBLICATION OF DATA AND PROTECTION OF TRADE SECRETS
 
The Principal Investigator (Protocol Chair) holds the primary responsib ility for 
publication of the study results; pr ovided that the PI [INVESTIGATOR_798750], Inc. for review at least sixty (60) days prior to submission and also comply
with any provisions regarding publication as are agreed to between the P Iâ€™s institution
(eg, institution name .) andExelixis, Inc. in the Clinical Trial Agreement related to this
study. The results will be made public within [ADDRESS_1101817] that meets the requirements of the International
Committee of Medical Journal Editors. In any event, a full report of the outcomes
should be made public no later than three (3) years after the end of data collection.
Authorship for abstracts and manuscripts resulting from thisstudy will be determined
according to guidelines established by [CONTACT_798779].
Protocol 2012-0252
November 11, 2016
Page 41
 
13.0 REFERENCES
 
 
(1)  Smith DC, Smith MR, Small EJ, Sweeney C, Kurzrock R, Gordon MS, e t al. Phase II 
study of XL184 in a cohort of patients ( pts) with castration-resistant prostate cancer 
(CRPC) and measurable soft tissue disease. J Clin Oncol 29: 2011 (supp l 7; abstr 127) .
2-17-2011. Ref Type: Generic
 
(2)  Pi[INVESTIGATOR_64982], Troncoso P, Zhau HE, Li W, von Eschenbach AC, Chung LW . c-met proto-
oncogene expression in benign and ma lignant human prostate tissues. J Ur ol
1995;154:293-8.
 
(3)  Knudsen BS, Gmyrek GA, Inra J, Scherr DS, Vaughan ED, Nanus DM , et al. High 
expression of the Met receptor in pro state cancer metastasis to bone. Uro logy
2002;60:1113-7.
 
(4)  Knudsen BS, Edlund M. Prostat e cancer and the met hepatocyte grow th factor receptor.
Adv Cancer Res 2004;91:31-67.
 
(5)  Loblaw DA, Virgo KS, Nam R, Somerfield MR, Ben-Josef E, Mendels on DS, et al.
Initial hormonal management of androgen-sensitive metastatic, recurr ent, or progressive
prostate cancer: 2006 update of an American Society of Clinical Oncolo gy practice
guideline. J Clin Oncol 2007;25:1596-605.
 
(6)  Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Canc er J Clin 2010;60:277-
300.
 
(7)  Scher HI, Sawyers CL. Biology of progressive, castration-resis tant prostate cancer:
directed therapi[INVESTIGATOR_798751]-receptor signaling axis. J C lin Oncol
2005;23:8253-61.
 
(8)  Karlou M, Tzelepi V, Efstathiou E. Therapeutic targeting of the p rostate cancer 
microenvironment. Nat Rev Urol 2010;7:494-509.
 
(9)  Efstathiou E, Logothetis CJ. A new therapy paradigm for prostat e cancer founded on
clinical observations. C lin Cancer Res 2010;16:1100-7.
 
(10)  Verras M, Lee J, Xue H, Li TH, Wang Y, Sun Z. The androgen recep tor negatively 
regulates the expression of c-Met: implications for a novel mechanism of  prostate cancer 
progression. Cancer Res 2007;67:967-75.
 
(11)  Tu WH, Zhu C, Clark C, Christensen JG, Sun Z. Efficacy of c-Met inh ibitor for advanced 
prostate cancer. BMC Cancer 2010;10:556.
 
(12) Millikan RE, Wen S, Pagliaro LC, Brown MA, Moomey B, Do KA, et al. Ph ase III trial
of androgen ablation with or without th ree cycles of systemic chemothe rapy for advanced 
prostate cancer. J Clin Oncol 2008;26:5936-42.
 